Opium (Opioid) Addiction - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 91 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Opium (Opioid) Addiction - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Opium (Opioid) Addiction - Pipeline Review, H1 2016', provides an overview of the Opium (Opioid) Addiction pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction
- The report reviews pipeline therapeutics for Opium (Opioid) Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Opium (Opioid) Addiction therapeutics and enlists all their major and minor projects
- The report assesses Opium (Opioid) Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Content
Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Opium (Opioid) Addiction Overview 9
Therapeutics Development 10
Pipeline Products for Opium (Opioid) Addiction - Overview 10
Pipeline Products for Opium (Opioid) Addiction - Comparative Analysis 11
Opium (Opioid) Addiction - Therapeutics under Development by Companies 12
Opium (Opioid) Addiction - Therapeutics under Investigation by Universities/Institutes 13
Opium (Opioid) Addiction - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Opium (Opioid) Addiction - Products under Development by Companies 17
Opium (Opioid) Addiction - Products under Investigation by Universities/Institutes 18
Opium (Opioid) Addiction - Companies Involved in Therapeutics Development 19
Alkermes Plc 19
Aoxing Pharmaceutical Company, Inc 20
BioDelivery Sciences International, Inc. 21
Camurus AB 22
Foresee Pharmaceuticals, LLC 23
Heron Therapeutics, Inc. 24
Indivior Plc 25
INSYS Therapeutics, Inc. 26
Omeros Corporation 27
Pfizer Inc. 28
Relmada Therapeutics, Inc. 29
Titan Pharmaceuticals, Inc. 30
Zynerba Pharmaceuticals, Inc. 31
Opium (Opioid) Addiction - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
(buprenorphine hydrochloride + samidorphan l-malate) - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Buprenorphine Hemiadipate Hydrochloride - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
buprenorphine hydrochloride - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
buprenorphine hydrochloride - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
buprenorphine hydrochloride - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
buprenorphine hydrochloride depot - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
buprenorphine hydrochloride ER - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
buprenorphine hydrochloride long acting - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
buprenorphine hydrochloride SR - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
cannabidiol - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Cannabidiol - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
FP-004 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
naltrexone hydrochloride - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
naltrexone hydrochloride - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
OMS-405 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
OMS-527 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
PF-5006739 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
samidorphan l-malate - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
TA-CD - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Vaccine for Opium Addiction - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Opium (Opioid) Addiction - Recent Pipeline Updates 72
Opium (Opioid) Addiction - Dormant Projects 81
Opium (Opioid) Addiction - Discontinued Products 82
Opium (Opioid) Addiction - Product Development Milestones 83
Featured News & Press Releases 83
Mar 04, 2016: BioDelivery Sciences to provide an update on Buprenorphine Injection at the Cowen And Company 36th Annual Healthcare Conference and the 28th Annual Roth Conference 83
Feb 19, 2016: Titan Pharmaceuticals Announces Notification of FDA Action Date Extension for Probuphine 83
Feb 16, 2016: TSRI Scientists Create Vaccine Against Dangerous Designer Opioids 83
Jan 13, 2016: Segal Institute for Clinical Research Proudly Participates in Phase 3 Efficacy Trial of Long-Acting Treatment Opioid Dependence 85
Jan 12, 2016: Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce FDA Advisory Committee Recommends Approval of Probuphine, First 6-Month Implant to Treat Opioid Addiction 85
Dec 30, 2015: Braeburn Pharmaceuticals and Camurus Enroll First Patient in a Phase 3 Efficacy Trial of Long-Acting Treatment for Opioid Dependence 86
Dec 15, 2015: Braeburn Pharmaceuticals and Camurus announce start of Phase 3 trial of long-acting buprenorphine treatments for opioid dependence 87
Dec 09, 2015: Braeburn Pharmaceuticals and Titan Pharmaceuticals Announce Date of FDA Advisory Committee Review of Probuphine for Opioid Addiction 87
Dec 09, 2015: Relmada Therapeutics Announces Positive Topline Results for Proof-of-Concept Study with BuTab 88
Dec 09, 2015: Relmada Therapeutics Announces Positive Topline Results for Proof-of-Concept Study with BuTab 88
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91

List of Tables

Number of Products under Development for Opium (Opioid) Addiction, H1 2016 10
Number of Products under Development for Opium (Opioid) Addiction - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Opium (Opioid) Addiction - Pipeline by Alkermes Plc, H1 2016 19
Opium (Opioid) Addiction - Pipeline by Aoxing Pharmaceutical Company, Inc, H1 2016 20
Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International, Inc., H1 2016 21
Opium (Opioid) Addiction - Pipeline by Camurus AB, H1 2016 22
Opium (Opioid) Addiction - Pipeline by Foresee Pharmaceuticals, LLC, H1 2016 23
Opium (Opioid) Addiction - Pipeline by Heron Therapeutics, Inc., H1 2016 24
Opium (Opioid) Addiction - Pipeline by Indivior Plc, H1 2016 25
Opium (Opioid) Addiction - Pipeline by INSYS Therapeutics, Inc., H1 2016 26
Opium (Opioid) Addiction - Pipeline by Omeros Corporation, H1 2016 27
Opium (Opioid) Addiction - Pipeline by Pfizer Inc., H1 2016 28
Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics, Inc., H1 2016 29
Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals, Inc., H1 2016 30
Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016 31
Assessment by Monotherapy Products, H1 2016 32
Assessment by Combination Products, H1 2016 33
Number of Products by Stage and Target, H1 2016 35
Number of Products by Stage and Mechanism of Action, H1 2016 37
Number of Products by Stage and Route of Administration, H1 2016 39
Number of Products by Stage and Molecule Type, H1 2016 41
Opium (Opioid) Addiction Therapeutics - Recent Pipeline Updates, H1 2016 72
Opium (Opioid) Addiction - Dormant Projects, H1 2016 81
Opium (Opioid) Addiction - Discontinued Products, H1 2016 82